

Ref: IIL/ 19-20/ _____

October 1, 2019

**The General Manager,
Pakistan Stock Exchange Limited,
Stock Exchange Building,
Stock Exchange Road,
Karachi**

**The Director (Enforcement Department),
Securities & Exchange Commission of Pakistan,
7th Floor, NIC Building,
Jinnah Avenue, Blue Area,
Islamabad**

Subject: **Material Information**

Dear Sir,

In accordance with the requirements of applicable provisions of the Securities Act, 2015, Listing Regulations of Stock Exchange and other relevant laws, we hereby convey the following information:

The Board of Directors of **Ismail Industries Limited** (hereinafter referred to as the "**Company**") in its meeting held on September 30, 2019 has approved following:

The Board has decided to further increase the long-term equity investment in its subsidiary company M/s. Hudson Pharma (Private) Limited as approved by the shareholders in 30th Annual General Meeting of the Company from Rs. 500,000,000/- (Rupees: Five hundred million only) to Rs. 1,000,000,000/- (Rupees: One billion only) in order to meet its operational expenses/working capital requirements under section 199 of the Companies Act, 2017, subject to approval of shareholders and Regulatory Authorities.

A disclosure form is enclosed herewith.

Regards,

For **Ismail Industries Limited**

(**Ghulam Farooq**)

Company Secretary

Encl: As Above



DISCLOSURE FORM**IN TERMS OF THE SECURITIES ACT, 2015**


Name of Company	Ismail Industries Limited
Date of Report	October 1, 2019
Name of Company as specified in its Memorandum	Ismail Industries Limited
Address of Registered Office	17, Bangalore Town, Main Shahra-e-Faisal, Karachi.
Contact Information	Mr. Ghulam Farooq Company Secretary 17, Bangalore Town, Main Shahra-e-Faisal, Karachi. Telephone number : 021-34311172-5 Fax number : 021-34547843 Email address : secretarialcompliance@ismailindustries.com

Disclosure of inside information by Listed Company in terms of Securities Act, 2015

1. The Board has decided to further increase the long-term equity investment in its subsidiary company M/s. Hudson Pharma (Private) Limited as approved by the shareholders in 30th Annual General Meeting of the Company from Rs. 500,000,000/- (Rupees: Five hundred million only) to Rs. 1,000,000,000/- (Rupees: One billion only) in order to meet its operational expenses/working capital requirements under section 199 of the Companies Act, 2017, subject to approval of shareholders and Regulatory Authorities.

The Company has duly caused this form / statement to be signed on its behalf by the undersigned hereunto duly authorized.

October 1, 2019


Ghulam Farooq
Company Secretary